BVT Put 195 IDP 21.06.2024/ DE000VD4A6Y7 /
2024-05-30 8:05:00 PM | Chg.-0.120 | Bid9:59:25 PM | Ask9:59:25 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.160EUR | -42.86% | - Bid Size: - |
- Ask Size: - |
BIOGEN INC. DL -,000... | 195.00 - | 2024-06-21 | Put |
GlobeNewswire
05-30
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...
GlobeNewswire
05-22
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...
GlobeNewswire
05-16
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire
05-15
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire
04-25
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
GlobeNewswire
04-23
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire
03-06
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire
03-04
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire
02-23
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
GlobeNewswire
02-12
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...
GlobeNewswire
02-08
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
GlobeNewswire
2023-12-19
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European C...
GlobeNewswire
2023-12-15
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Fri...
GlobeNewswire
2023-12-14
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is...